Hematologic Cancers: start in blood-forming tissue, such as the bone marrow and cells of the immune system and can affect the blood and lymph system. A few examples of hematologic cancers are leukemia, lymphoma, and multiple myeloma.
-
NOV 30, 2023 | 12:00 PM
C.E. CREDITS
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
September 13 at 10:00am CEST, 9:00am BST
Webinar airing too early or too late for you? This webinar will also be available: September 13 at 10:00am PDT, 1:00pm EDT https://www.labroots.com/ms/webinar/dpcr-liquidbiopsy-panel-2 and S...
September 13 at 9:30am IST, 12:00pm CST/SGT
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...
Date: March 23, 2023 Time: 8:00am (PDT), 11:00am (EDT), 8:00pm (CEST) Across clinical oncology applications, from molecular testing to cancer research the ability to identify potentially act...
Date: January 25, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Allogeneic hematopoietic cell transplantation (HCT) is curative for hematological diseases; however, is also associated...
DEC 14, 2022 | 12:00 PM
C.E. CREDITS
Date: December 14, 2022 Time: 12:00pm (PST), 3:00pm (EST), 9:00pm (CET) Adopting novel technologies is essential for improving patient outcomes, but the key to sustainable success is through...
OCT 19, 2022 | 10:00 AM
C.E. CREDITS
Date: October 19, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 7:00pm (CEST) In this webinar, we will introduce the generation and applications of Biocytogen’s severely immunodeficient (B-N...
Accurate classification of genetic alterations is important to ensure the provision of high-quality clinical data. For interpretation of germline alterations, there are standardized guidelin...
Date: April 14, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify...
Date: November 30, 2021 Time: 11:00am (PDT), 2:00pm (EDT) In the recent years, measurable residual disease (MRD) assessment on multiple myeloma patients has gained increasing relevance. After...
Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clini...
Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular...